Tepotinib联合吉非替尼治疗EGFR突变伴MET过表达或扩增的NSCLC:INSIGHT研究
INSIGHT研究是一项开放标签、1b/2期随机试验,评估Tepotinib联合吉非替尼对比标准化疗在EGFR突变、MET过表达或扩增且对既往EGFR抑制剂获得性耐药的NSCLC患者中的疗效与安全性。2期因招募缓慢提前终止,探索性分析显示在MET过表达(IHC3+)或MET扩增亚组中,联合治疗较化疗延长PFS和OS。
要点
- 联合治疗在MET IHC3+或MET扩增亚组中PFS和OS优于化疗。
- 总体人群PFS和OS无显著差异,研究提前终止。
- 安全性方面,联合组常见3级及以上不良事件为淀粉酶和脂肪酶升高。
核心结论
- 尽管研究提前终止,预定义亚组分析提示,在EGFR突变且MET扩增的NSCLC患者中,Tepotinib联合吉非替尼较标准化疗可能改善抗肿瘤活性。
研究设计与样本
- 开放标签、1b/2期、多中心、随机试验(INSIGHT),纳入成人晚期或转移性NSCLC患者,ECOG PS 0或1,来自亚洲六国。
- 1b期患者接受口服Tepotinib 300 mg或500 mg联合吉非替尼250 mg每日一次;2期患者随机(初始1:1,后改为2:1)接受推荐2期剂量Tepotinib联合吉非替尼或标准化疗(铂类双药)。
- 主要终点为研究者评估的PFS,次要终点包括OS和安全性;因招募缓慢,2期提前终止,所有分析为探索性。
主要发现
- 1b期18例(300 mg组6例,500 mg组12例),2期55例(联合组31例,化疗组24例);1b期未观察到剂量限制性毒性,推荐2期剂量为Tepotinib 500 mg。
- 联合组最常见的治疗相关3级及以上不良事件为淀粉酶升高(5/31,16%)和脂肪酶升高(4/31,13%);化疗组为贫血(7/23,30%)和中性粒细胞计数降低(3/23,13%)。
关键数值与推荐
- MET过表达定义为免疫组化(IHC)2+或3+;MET扩增定义为平均基因拷贝数≥5或MET/7号染色体着丝粒比值≥2。
- 推荐2期剂量为Tepotinib 500 mg口服每日一次联合吉非替尼250 mg口服每日一次。
临床怎么用
- 对于EGFR突变NSCLC患者经EGFR抑制剂治疗后进展且存在MET扩增或高表达(IHC3+),可考虑Tepotinib联合吉非替尼作为探索性治疗选择。
- 治疗期间需监测淀粉酶、脂肪酶等不良事件。
局限性
- 2期因招募缓慢提前终止,样本量小,所有分析均为探索性。
- 研究未达到主要终点,总体人群PFS和OS无显著差异。
- 亚组分析为预定义但样本量有限,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or MET amplification having acquired resistance to EGFR inhibition. METHODS: In this open-label, phase 1b/2, multicentre, randomised trial (the INSIGHT study), we enrolled adult patients (≥18 years) with advanced or metastatic NSCLC, and Eastern Cooperative Oncology Group performance status of 0 or 1, from academic medical centres and community clinics in six Asian countries. In phase 1b, patients received oral tepotinib 300 mg or 500 mg plus gefitinib 250 mg once daily. In phase 2, patients with EGFR-mutant, T790M-negative NSCLC MET overexpression or MET amplification were randomly assigned (initially in a 1:1 ratio and then 2:1 following a protocol amendment) to tepotinib plus gefitinib at the recommended phase 2 dose or to standard platinum doublet chemotherapy. Randomisation was done centrally via an interactive voice-response system. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS) and safety. Subgroup analyses were preplanned in patients with high MET overexpression (IHC3+) or MET amplification (mean gene copy number ≥5 or MET to centromere of chromosome 7 ratio ≥2). Efficacy and patient characteristics were assessed on an intention-to-treat basis and safety was assessed for all patients who received at least one dose of study medication. Low recruitment led to early termination of phase 2, so all analyses are considered to be exploratory. This study is registered with ClinicalTrials.gov, NCT01982955, and the European Union Drug Regulating Authorities Clinical Trials Database, Eudra-CT 2016-001604-28. FINDINGS: From Dec 23, 2013, to May 25, 2017, 18 patients were enrolled in phase 1b (n=6 in the 300 mg tepotinib group; n=12 in the 500 mg tepotinib group) and 55 patients in phase 2 (n=31 in the tepotinib plus gefitinib group; n=24 in the chemotherapy group). No dose-limiting toxicities were observed in phase 1b, so tepotinib 500 mg was used as the recommended phase 2 dose. In phase 2, survival outcomes were similar between groups: median PFS was 4·9 months in the tepotinib plus gefitinib group (90% CI 3·9-6·9) versus 4·4 months in the chemotherapy group (90% CI 4·2-6·8; hazard ratio [HR] 0·67, 90% CI 0·35-1·28). Median OS was 17·3 months in the tepotinib plus gefitinib group (12·1-37·3) versus 18·7 months in the chemotherapy group (15·9-20·7; HR 0·69, 0·34-1·41). PFS and OS were longer with tepotinib plus gefitinib than with chemotherapy in patients with high (IHC3+) MET overexpression (n=34; median PFS 8·3 months [4·1-16·6] vs 4·4 months [4·1-6·8]; HR 0·35, 0·17-0·74; median OS 37·3 months [90% CI 24·2-37·3] vs 17·9 months [12·0-20·7]; HR 0·33, 0·14-0·76) or MET amplification (n=19; median PFS 16·6 months [8·3-not estimable] vs 4·2 months [1·4-7·0]; HR 0·13, 0·04-0·43; median OS 37·3 months [90% CI not estimable] vs 13·1 months [3·25-not estimable]; HR 0·08, 0·01-0·51). The most frequent treatment-related grade 3 or worse adverse events were increased amylase (5 [16%] of 31 patients) and lipase (4 [13%]) concentrations in the tepotinib plus gefitinib group and anaemia (7 [30%] of 23 patients) and decreased neutrophil count (3 [13%]) in the chemotherapy group. INTERPRETATION: Despite early study termination, in a preplanned subgroup analysis, our findings suggest improved anti activity for tepotinib plus gefitinib compared with standard chemotherapy in patients with EGFR-mutant NSCLC and MET amplification, warranting further exploration. FUNDING: Merck KGaA.
引用
- Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020. PMID: 32479794. doi:10.1016/S2213-2600(20)30154-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。